Clinical trials
PSMA Positive Tumors or Tumor Tissues clinical trials
Below are recruiting psma positive tumors or tumor tissues clinical trials, each written for real people, not researchers. We’re tracking 1,296 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06682780RecruitingPhase 1/Phase 2
Testing LM-2417 for advanced solid tumors
This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06687070RecruitingPhase 1
APG-2449 alone or with PLD for advanced cancers
This trial tests a new drug, APG-2449, either alone or with another chemotherapy called PLD (pegylated liposomal doxorubicin). It is for people with advanced solid tumors, including ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is.
Guangzhou, GuangdongAges 18 years+ - NCT05906862RecruitingPhase 1
AMT-253 for advanced solid tumors after standard treatments
This Phase 1 study tests AMT-253, an experimental drug, in people with advanced solid cancers that have grown despite prior treatment (or where standard options were not tolerated). The goal is to find a safe dose and learn how the drug affects the cancer.
Sydney, New South WalesAges 18 years+ - NCT06674538Enrolling by invitationPhase 1
Antibody trial for advanced solid tumors
This trial tests an antibody treatment for people with stage IV cancer that has not responded to previous treatment. It aims to find a new option for patients with several types of advanced solid tumors.
Hershey, PennsylvaniaAges 18 years+ - NCT06680596Enrolling by invitationPhase 2
Blood test to find T-DXd candidates for breast cancer
This trial uses a blood test to look for tumor DNA in women with a certain type of advanced breast cancer (HR-positive, HER2-low). If the DNA doesn't disappear after starting standard hormone therapy with a CDK4/6 inhibitor, participants may be switched to a targeted drug called T-DXd (trastuzumab deruxtecan).
AmiensAges 18 years+ - NCT06659341RecruitingPhase 1
Study of BAY3498264 with Sotorasib for KRAS G12C Cancers
This trial tests a new drug (BAY3498264) combined with sotorasib, a targeted therapy, for people with advanced cancers that have a specific genetic change called KRAS G12C. It's for those who have already tried other treatments and need new options.
Albury, New South WalesAges 18 years+ - NCT06667544RecruitingPhase 1/Phase 2
Study of RNK08954 for advanced cancers with KRAS G12D mutation
This trial tests a new oral drug called RNK08954 for people with advanced solid tumors that have a specific KRAS G12D genetic change. The drug targets this mutation to try to stop tumor growth. It is for patients who have already had other treatments and may not have many options left.
Nanning, GuangxiAges 18 years+ - NCT06667960RecruitingPhase 1/Phase 2
Study of JK06 for advanced solid tumors
This trial tests a new drug called JK06 for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if JK06 is safe and effective.
AntwerpAges 18 years+ - NCT06649292RecruitingPhase 3
Study of SHR-A1904 for gastric cancer with CLDN18.2
This trial tests a new drug called SHR-A1904 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has already been treated once. It is for those whose tumors are positive for a protein called CLDN18.2.
Guangzhou, GuangdongAges 18–75 - NCT06646627RecruitingPhase 1
B7-H3 car t cells for platinum-resistant ovarian cancer
This trial tests a new treatment where your own immune cells are modified to attack ovarian cancer cells that have stopped responding to platinum chemotherapy. It's for people with recurrent ovarian cancer that hasn't gotten better with standard treatments.
Palo Alto, CaliforniaAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Birmingham, AlabamaAges 18 years+ - NCT06596915RecruitingPhase 1
BA1302 for advanced solid tumors
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
BeijingAges 18 years+ - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Duarte, CaliforniaAges 18 years+ - NCT03878849RecruitingPhase 2
Study drug 2X-121 for ovarian cancer that keeps coming back
This Phase 2 trial tests whether 2X-121 can shrink or control ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum chemotherapy. It enrolls people who have had limited prior treatment and can provide a recent or stored tumor sample.
Oklahoma City, OklahomaAges 18 years+ - NCT06562647Recruiting
Testing SY001 for advanced ovarian or pancreatic cancer with mesothelin
This trial tests a new drug called SY001, which targets a protein called mesothelin found on some cancer cells. It is designed for people with advanced ovarian or pancreatic cancer who have already tried other treatments and whose tumor tissue has mesothelin.
Hangzhou, ZhejiangAges 18–75 - NCT06552260RecruitingEarly Phase 1
Troriluzole before surgery for recurrent glioblastoma
This trial tests whether an investigational drug called troriluzole can help people with recurrent glioblastoma (a type of brain tumor). You would take the drug for a short time before your planned surgery, so researchers can study how the drug affects your tumor tissue. The goal is to see if it might slow tumor growth.
Boston, MassachusettsAges 18 years+ - NCT06551116Recruiting
Better HER2 testing for HER2-low breast cancer on Enhertu
This study looks at using a more detailed lab test to measure HER2 levels in people with HER2-low metastatic breast cancer who are starting or have just started treatment with Enhertu. The goal is to see if this test can help doctors better understand who might benefit from Enhertu.
San Francisco, CaliforniaAges 18 years+ - NCT05900206RecruitingPhase 2
Trastuzumab deruxtecan vs standard chemotherapy before breast surgery
This Phase 2 study compares trastuzumab deruxtecan to standard chemotherapy given before surgery for HER2-positive breast cancer. It aims to see which treatment works better to shrink the tumor and spread before the operation.
MalmöAges 18 years+ - NCT06534060RecruitingPhase 2
Testing MB-105 for CD5 positive T-cell lymphoma
This trial tests a new treatment called MB-105 for people with a type of T-cell lymphoma that has come back or not responded to other treatments. MB-105 is designed to target and attack cancer cells that have a specific marker called CD5 on their surface.
San Diego, CaliforniaAges 18 years+ - NCT06536257Recruiting
Personalized immunotherapy prediction for melanoma and other cancers
This trial is testing a new way to predict which immunotherapy might work best for your cancer. It uses a sample of your tumor to look for personal markers, so your treatment can be tailored to you.
Sydney, New South WalesAges 18 years+ - NCT06522932RecruitingPhase 1
PET imaging study for people getting CAR-T therapy for lymphoma
This trial tests a special PET imaging agent (64Cu-GRIP B) to see if it can help track how well CAR-T therapy is working in people with non-Hodgkin lymphoma. It is for patients who have had at least one prior treatment and are scheduled to receive a standard CD19-targeting CAR-T product.
San Francisco, CaliforniaAges 18 years+ - NCT06209580RecruitingPhase 1/Phase 2
Testing AMT-253 for advanced solid tumors
This study tests an experimental drug AMT-253 in people with advanced solid tumors (like melanoma) that have progressed despite prior treatment. The goal is to see if the drug can help shrink or slow the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05622409Recruiting
Tissue and genetic data registry for diffuse glioma in adults
This study collects tumor tissue and basic medical information to better understand the genes involved in adult diffuse glioma. It may help future treatments by building a detailed research database and matching patients to study arms.
Kaohsiung CityAges 20 years+ - NCT06500819RecruitingPhase 1
B7-H3 CAR T cells for relapsed solid tumors
This trial tests a new immune therapy using your own cells (called B7-H3 CAR T cells) to treat solid tumors that haven't responded to other treatments. It may help children and young adults with certain cancers that are hard to cure.
Palo Alto, CaliforniaAges 2–30
Hear when a new PSMA Positive Tumors or Tumor Tissues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma positive tumors or tumor tissues?
- Yes. Clin2 currently lists 1,296 recruiting psma positive tumors or tumor tissues studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma positive tumors or tumor tissues trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma positive tumors or tumor tissues trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.